Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Hypertriglyceridemia secondary to obesity and diabetes.

Subramanian S, Chait A.

Biochim Biophys Acta. 2012 May;1821(5):819-25. doi: 10.1016/j.bbalip.2011.10.003. Epub 2011 Oct 8. Review.

PMID:
22005032
2.
3.

Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.

Ito MK.

Atherosclerosis. 2015 Oct;242(2):647-56. doi: 10.1016/j.atherosclerosis.2015.06.012. Epub 2015 Jun 11. Review.

PMID:
26296750
4.

Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus.

Sniderman AD, Scantlebury T, Cianflone K.

Ann Intern Med. 2001 Sep 18;135(6):447-59. Review.

PMID:
11560458
5.

Triglyceride Lowering Drugs.

Feingold K, Grunfeld C.

In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2017 Jan 20.

6.

[Diabetic dyslipidaemia and the atherosclerosis].

Márk L, Dani G.

Orv Hetil. 2016 May 8;157(19):746-52. doi: 10.1556/650.2016.30441. Review. Hungarian.

PMID:
27133274
7.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165
8.

[Diabetic dyslipoproteinemia].

Geiss HC, Parhofer K.

MMW Fortschr Med. 2006 Apr 6;148(14):30-3. German.

PMID:
16669277
9.

Triglycerides to high-density lipoprotein-cholesterol ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes.

Quispe R, Martin SS, Jones SR.

Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):150-6. doi: 10.1097/MED.0000000000000241. Review.

PMID:
26863278
10.

Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia.

Guérin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ.

Arterioscler Thromb Vasc Biol. 2001 Feb;21(2):282-8.

11.

Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.

Krentz AJ.

Diabetes Obes Metab. 2003 Nov;5 Suppl 1:S19-27. Review.

PMID:
14984018
12.

Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.

Yki-Järvinen H.

Dig Dis. 2010;28(1):203-9. doi: 10.1159/000282087. Epub 2010 May 7. Review.

PMID:
20460912
13.

Statins and diabetes.

Carmena R, Betteridge DJ.

Semin Vasc Med. 2004 Nov;4(4):321-32. Review.

PMID:
15861314
14.

Management of hypertriglyceridemia in the diabetic patient.

Jialal I, Amess W, Kaur M.

Curr Diab Rep. 2010 Aug;10(4):316-20. doi: 10.1007/s11892-010-0124-4. Review.

15.

Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events.

McCullough PA, Ahmed AB, Zughaib MT, Glanz ED, Di Loreto MJ.

Rev Cardiovasc Med. 2011;12(4):173-85. doi: 10.3909/ricm0619. Review.

PMID:
22249508
18.
19.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901
20.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279

Supplemental Content

Support Center